Skip to main content

Advertisement

Table 3 Comparison of pooled PCR-uncorrected proportions of adequate clinical and parasitological response between AQ-SP and ACT.

From: Efficacy of non-artemisinin- and artemisinin-based combination therapies for uncomplicated falciparum malaria in Cameroon

ACT Odds-ratio (95% CI), as compared to AQ-SP
day 2 day 3 day 14 day 28
AM-LM 25.6 (8.21-79.5)* ND 2.81 (0.28-27.7) 6.32 (1.35-29.6)*
AS-AQ 26.4 (12.4-56.4)* 16.0 (3.35-76.1)* 0.72 (0.20-2.62) 0.80 (0.40-1.61)
AS-CD 34.7 (11.2-107)* ND 0.26 (0.07-0.96)* 0.35 (0.16-0.75)*
AS-MQ 11.4 (4.76-27.1)* 3.26 (0.84-12.7) 0.36 (0.10-1.41) 1.45 (0.57-3.71)
AS-SP 18.9 (8.64-41.2)* 5.30 (1.57-17.9)* 0.91 (0.22-3.64) 1.34 (0.60-2.93)
DH-PP 37.4 (12.2-115)* ND 0.80 (0.18-3.50) 9.16 (2.0-42.5)*
  1. Patients who were excluded or lost-to-follow-up were not included in the analysis. Data from a total of 709 patients were analysed, with treatment as a single covariate. Asterisks denote P < 0.05. ND (not done) denotes infinite OR due to 100% ACPR. On day 7, 100% ACPR was observed with all bitherapies. ACT, artemisinin-based combination therapies; AS-AQ, artesunate-amodiaquine; AS-MQ, artesunate-mefloquine; AS-SP, artesunate-sulphadoxine-pyrimethamine; AM-LM, artemether-lumefantrine; AS-CD, artesunate-chlorproguanil-dapsone; DH-PP, dihydroartemisinin-piperaquine; AQ-SP, amodiaquine-sulphadoxine-pyrimethamine.